Patents by Inventor Michael Goldstein

Michael Goldstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrrolo[2,3-b]pyrazines as JAK3 inhibitors
    Patent number: 9676778
    Abstract: The present disclosure provides compounds of formula (I) wherein the variables are as defined herein that are JAK3 inhibitors and therefore useful for the treatment of diseases treatable by inhibition of JAK3 such as cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: June 13, 2017
    Assignee: PRINCIPIA BIOPHARMA INC.
    Inventors: David Michael Goldstein, Kenneth Albert Brameld, Tim Owens
  • Computer Architecture and Method for Modifying Intake Data Rate Based on a Predictive Model
    Publication number: 20170161130
    Abstract: Disclosed herein is a computer architecture and software that is configured to modify data intake operation at an asset-monitoring system based on a predictive model. In accordance with the present disclosure, the asset-monitoring system may execute a predictive model that outputs an indicator of whether at least one event from a group of events (e.g., a failure event) is likely to occur at a given asset within a given period of time in the future. Based on the output of this predictive model, the asset-monitoring system may modify one or more operating parameters for ingesting data from the given asset, such as a storage location for the ingested data, a set of data variables from the asset that are ingested, and/or a rate at which data from the asset is ingested.
    Type: Application
    Filed: December 8, 2015
    Publication date: June 8, 2017
    Inventors: Michael Goldstein, Tom Ravensberg, Will Hansmann
  • Computer Architecture and Method for Modifying Intake Data Set Based on a Predictive Model
    Publication number: 20170161621
    Abstract: Disclosed herein is a computer architecture and software that is configured to modify data intake operation at an asset-monitoring system based on a predictive model. In accordance with the present disclosure, the asset-monitoring system may execute a predictive model that outputs an indicator of whether at least one event from a group of events (e.g., a failure event) is likely to occur at a given asset within a given period of time in the future. Based on the output of this predictive model, the asset-monitoring system may modify one or more operating parameters for ingesting data from the given asset, such as a storage location for the ingested data, a set of data variables from the asset that are ingested, and/or a rate at which data from the asset is ingested.
    Type: Application
    Filed: December 8, 2015
    Publication date: June 8, 2017
    Inventors: Michael Goldstein, Tom Ravensberg, Will Hansmann
  • Computer Architecture and Method for Modifying Data Intake Storage Location Based on a Predictive Model
    Publication number: 20170161659
    Abstract: Disclosed herein is a computer architecture and software that is configured to modify data intake operation at an asset-monitoring system based on a predictive model. In accordance with the present disclosure, the asset-monitoring system may execute a predictive model that outputs an indicator of whether at least one event from a group of events (e.g., a failure event) is likely to occur at a given asset within a given period of time in the future. Based on the output of this predictive model, the asset-monitoring system may modify one or more operating parameters for ingesting data from the given asset, such as a storage location for the ingested data, a set of data variables from the asset that are ingested, and/or a rate at which data from the asset is ingested.
    Type: Application
    Filed: December 8, 2015
    Publication date: June 8, 2017
    Inventors: Michael Goldstein, Tom Ravensberg, Will Hansmann
  • Computer Systems and Methods for Governing a Network of Data Platforms
    Publication number: 20170085627
    Abstract: Disclosed herein are systems, devices, and methods for governing data platforms that are communicatively coupled via a network. According to an example, a first platform may receive, from a second platform (e.g., a master or seed platform), criteria that governs whether the first platform is permitted to share asset-related data with one or more other platforms in the network and assess the reliability of the platform's stored asset-related data. In turn, the first platform may apply the criteria to the assessed reliability to determine whether the first platform is permitted to share asset-related data with the one or more other platforms and then operate in accordance with that determination.
    Type: Application
    Filed: September 16, 2016
    Publication date: March 23, 2017
    Inventors: Michael Goldstein, Will Hansmann, Tom Ravensberg, Jason Kolb
  • Computer Systems and Methods for Sharing Asset-Related Information Between Data Platforms Over a Network
    Publication number: 20170085661
    Abstract: Disclosed herein are systems, devices, and methods for sharing asset-related information between data platforms that are communicatively coupled via a network. According to an example, a first platform may receive asset-related data and determine that a portion of the received data should be pushed to another platform. Based on that determination, the first platform may prepare a portion of the received data to be transmitted to another platform and then push the portion of the data to another platform over a network connection.
    Type: Application
    Filed: September 16, 2016
    Publication date: March 23, 2017
    Inventors: Michael Goldstein, Will Hansmann, Tom Ravensberg, Jason Kolb
  • Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
    Patent number: 9376438
    Abstract: The present disclosure provides compounds of Formula (I)and pharmaceutically acceptable salts that are tyrosine kinase inhibitors,in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: June 28, 2016
    Assignee: Principia Biopharma, Inc.
    Inventors: David Michael Goldstein, Kenneth Albert Brameld
  • SELF-ENCLOSED AIR VEHICLE
    Publication number: 20160176520
    Abstract: Vehicles such as unmanned air vehicles that are capable of movement from an open, flight configuration to an enclosed configuration in which all major flight components can be protected by an outer shell are disclosed. In the enclosed configuration, the vehicles can take on standard geometric shapes such as a rectangular prism, sphere, cylinder, or another shape, so as to not be recognizable as an unmanned air vehicle. Embodiments of vehicles can also include interchangeable and/or wireless motor arms, motor arms which are electrically connected to the remainder of the vehicle only when in an open configuration, remote controllers removably attached to the remainder of the vehicle, and clip or other attachment mechanisms for attachment to objects such as backpacks.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Inventor: Ryan Michael Goldstein
  • FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS
    Publication number: 20160045503
    Abstract: Oral pharmaceutical formulations comprising reversible covalent compounds having a Michael acceptor moiety, a process of their production and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.
    Type: Application
    Filed: June 11, 2013
    Publication date: February 18, 2016
    Inventors: David Michael Goldstein, Bret BERNER
  • TYROSINE KINASE INHIBITORS
    Publication number: 20150353557
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 6, 2015
    Publication date: December 10, 2015
    Applicant: Principia Biopharma Inc.
    Inventors: David Michael Goldstein, Kenneth Albert Brameld
  • TYROSINE KINASE INHIBITORS
    Publication number: 20150353562
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 16, 2015
    Publication date: December 10, 2015
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventor: David Michael GOLDSTEIN
  • AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS
    Publication number: 20150291600
    Abstract: The present disclosure provides compounds that are JAK3 inhibitors and therefore useful for the treatment of diseases treatable by inhibition of JAK3 such as cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: November 19, 2013
    Publication date: October 15, 2015
    Inventors: David Michael Goldstein, Kenneth Albert Brameld, Tim Owens
  • Tyrosine kinase inhibitors
    Patent number: 9090621
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: July 28, 2015
    Assignee: Principia Biopharma Inc.
    Inventor: David Michael Goldstein
  • FORMULATIONS COMPRISING IBRUTINIB
    Publication number: 20150140085
    Abstract: Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.
    Type: Application
    Filed: June 26, 2013
    Publication date: May 21, 2015
    Applicant: Principia Biopharma Inc.
    Inventor: David Michael Goldstein
  • Method of submitting information to a database concerning a stopped vehicle
    Patent number: 9020974
    Abstract: A law enforcement officer involved in a traffic stop is provided with a means to submit details of contraband locations within the stopped vehicle to a cloud-based server or database. This method of submitting information allows any other officer to be able to retrieve up-to-date information regarding the location of contraband hidden with a particular vehicle. The data submitted, stored, and accessed from the cloud-based server or database may include methods and instructions for accessing the hiding places, or other relevant information useful for an officer to retrieve contraband.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: April 28, 2015
    Inventor: Michael Goldstein
  • PROVIDING MUSICAL LYRICS AND MUSICAL SHEET NOTES THROUGH DIGITAL EYEWEAR
    Publication number: 20150053067
    Abstract: Described herein is an optical device for presenting music information. The optical device identifies an indication that a music piece is to begin playback. The optical device identifies music information associated with the music piece. The optical device presents the music information in synchronization with playback of the music piece.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 26, 2015
    Inventor: Michael Goldstein
  • Tyrosine kinase inhibitors
    Patent number: 8962635
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: February 24, 2015
    Assignee: Principia Biopharma Inc.
    Inventor: David Michael Goldstein
  • Benzotriazole kinase modulators
    Patent number: 8962622
    Abstract: Compounds of formula I modulate jnk and cdk: or a pharmaceutically acceptable salt thereof, where R, R1, R2, R3, and m are defined herein.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 24, 2015
    Assignee: Roche Palo Alto LLC
    Inventors: David Michael Goldstein, Levi Gong, Christophe Michoud, Wylie Solang Palmer, Achyutharao Sidduri
  • Tyrosine kinase inhibitors
    Patent number: 8962831
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: February 24, 2015
    Assignee: Principia Biopharma Inc.
    Inventor: David Michael Goldstein
  • Tyrosine kinase inhibitors
    Patent number: 8957080
    Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: February 17, 2015
    Assignee: Principia Biopharma Inc.
    Inventors: David Michael Goldstein, Kenneth Albert Brameld